GET DAILY SIGNALSSeer (SEER): Analyst Target at $4.00 Suggests +104% Upside Potential
Key Takeaways
- The central price target used here is $4.00, which reflects the arithmetic mean of a small set of current, verifiable analyst targets that cluster at $4.00.
- With the latest close near $1.96, reaching $4.00 would require a rise of roughly 104% — a very large move relative to the stock's recent trading range.
- Coverage is thin: only about two to three firms maintain current targets, and their figures show almost no spread, all landing at $4.00, so the "range" is effectively a single number rather than a genuine low-to-high spread.
- The strongest supporting factors are Seer's cash-heavy balance sheet, a market value below book value, and its Proteograph product suite, which is gaining validation through a growing body of peer-reviewed research.
- The biggest risks are persistent net losses, modest revenue scale, heavy reliance on research budgets, and the departure of senior leadership.
- For more context, readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Investors looking for AI-driven market analysis can also explore Trending AI Robots.
Analyst Price Targets and the Limited Consensus
Seer, Inc. (SEER) is a life sciences company that develops the Proteograph product suite, an integrated platform for deep, unbiased proteomic analysis. Analyst coverage of this small-cap is limited. Current tracked targets — from sources such as MarketBeat, MarketWatch, and Investing.com — center almost entirely on $4.00. Canaccord Genuity analyst Kyle Mikson initiated coverage with a Buy rating and a $4.00 target in May 2026 and reiterated that view in July 2026, while TD Cowen's Daniel Brennan has also maintained a Buy rating.
Because the handful of valid targets all sit at $4.00, the calculated mean is $4.00, and the practical low-to-high range is effectively flat. This is important context: the target is not a broad, diversified consensus but a small cluster of bullish views. Readers should treat $4.00 as a single, thin-coverage figure rather than a robust Wall Street average. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and the Path to the Target
Seer's stock last traded near $1.96, within a 52-week range of roughly $1.55 to $2.39. The company's market capitalization is about $108 million, while it held roughly $153 million in cash and investments as of its most recent quarter — meaning the business's enterprise value is slightly negative and the shares trade below book value (a price-to-book ratio near 0.5).
From about $1.96, reaching $4.00 would require a gain of approximately 104%, which qualifies as a very large move. Such a re-rating would almost certainly depend on a material acceleration in revenue, evidence that the Proteograph platform is converting research adoption into recurring commercial demand, and a decisive shift in how investors value an unprofitable but cash-rich company.
Factors That Could Support a Move Toward the Target
Several factors could underpin upward momentum. Seer's balance sheet is a notable cushion: cash and investments far exceed its market value, limiting near-term dilution risk. The company has surpassed 100 peer-reviewed customer publications, and researchers at Nanyang Technological University have presented early findings from the large-scale PRECISE-SG100K proteomics study, lending scientific credibility to the platform. A co-marketing partnership with Thermo Fisher Scientific extends commercial reach, and analysts framing a $4.00 target have cited expectations for higher revenue growth and improved profitability over time.
Obstacles That Could Keep the Target Out of Reach
The obstacles are equally real. Seer remains deeply unprofitable, with trailing-twelve-month revenue around $14 million against a net loss of roughly $68 million, and negative EPS (earnings per share) of about -$1.22. Demand is tied closely to academic, government, and biopharmaceutical research budgets, which can be sensitive to funding uncertainty. The announced departure of President and CFO David Horn in October 2026 introduces leadership transition risk. Finally, with analyst coverage thin and targets concentrated at a single level, there is little independent corroboration to support the bullish case.
Technical Levels and Market Structure
Seer shares are trading just above their 200-day simple moving average (around $1.92) but below the 50-day moving average (near $2.02), a configuration that suggests a long-term base but near-term hesitation. The 52-week high near $2.39 acts as the first meaningful resistance level and a psychological hurdle before any test of higher prices. The $1.55 area marks the recent support level and a key downside reference. A sustained move above $2.39 would be an early sign of shifting market structure, though it would still leave a long path to $4.00.
Time Horizon and Key Items to Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though with such thin coverage the implied timeframe should be treated with caution. The most immediate catalyst is Seer's third-quarter 2026 earnings report, scheduled for November 10, 2026. Investors should watch revenue trajectory, cash burn, gross margin, commentary on the Proteograph pipeline and partnerships, and any updates on the CFO transition. Any additions or changes to analyst coverage would also be significant, given how concentrated current targets are. From what I see, this earnings release will be an important checkpoint.
Using AI Daily Buy/Sell Signals in Research
When I review thinly covered names like this, Tickeron's AI Daily Buy/Sell Signals provide a useful layer of ongoing monitoring. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a stock with limited traditional coverage, it helps surface potential changes in trend without replacing fundamental work. I find it complements manual review effectively for names in this space.
Final Assessment
Can Seer, Inc. stock reach $4? The $4.00 central target — drawn from a small cluster of current analyst views, not a broad consensus — implies a roughly 104% advance from a price near $1.96, a very large move by any standard. The case rests on Seer's unusual cash-to-market-value profile, a sub-book-value valuation, and early scientific and commercial validation of its proteomics platform. Against that stand persistent losses, modest revenue, research-budget sensitivity, and leadership change. With analyst targets concentrated at a single level and no meaningful spread, investors have limited independent guidance. The outcome will hinge most on sustained revenue acceleration and evidence that the platform's adoption translates into durable commercial traction, beginning with the November earnings report.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SEER's Stochastic Oscillator remains in oversold zone for 8 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEER advanced for three days, in 162 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for SEER moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 17 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SEER as a result. In 65 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for SEER turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
SEER moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SEER crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
SEER broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SEER entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.481) is normal, around the industry mean (3.037). P/E Ratio (-1.607) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (7.800) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. SEER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement